Promoter hypermethylation of the p16 gene and loss of its protein expression is correlated with tumor progression in extrahepatic bile duct carcinomas

Archives of Pathology and Laboratory Medicine

Volumn 130, Issue 1, 2006, Pages 33-38

  Hong, Seung Mo ^a,b   Choi, Jene ^a   Ryu, Kyueun ^a   Ro, Jae Y ^a,c   Yu, Eunsil ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ARTICLE; BILE DUCT CARCINOMA; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CELL CYCLE REGULATION; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE INACTIVATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; DNA METHYLATION; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, P16; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICRODISSECTION; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); SURVIVAL RATE;

EID: 30444450833     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Carriaga MT, Henson DE. Liver, gallbladder, extrahepatic bile duct, and pancreas. Cancer. 1995;75:171-190.
2. Ministry of Health and Welfare, Korea. Survey report on cancer patients in 1992. Available at: http://www.mohw.go.kr/english/index.html, 1996. Accessed November 20, 2004.
3. Hidaka E, Yanagisawa A, Seki M, Setoguchi T, Kato Y. High frequency of K-ras mutations in biliary tract carcinomas of cases with a long common channel in the papilla of Vater. Cancer Res. 2000;60:522-524.
4. Malats N, Porta M, Pinol JL, Corominas JM, Rifa J, Real FX. Ki-ras mutations as a prognostic factor in extrahepatic bile system cancer, PANK-ras project investigators. J Clin Oncol. 1995;13:1679-1686.
5. Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002;8:3156-3163.
6. Suto T, Habano W, Sugai T, et al. Aberrations of the K-ras, p53, and APC genes in extrahepatic bile duct cancer. J Surg Oncol. 2000;73:158-163.
7. Rijken AM, van Gulik TM, Polak MM, Sturm PD, Gouma DJ, Offerhaus GJ. Diagnosis and prognostic value of incidence of K-ras codon 12 mutation in resected distal bile duct carcinoma. J Surg Oncol. 1998;68:187-192.
8. Rashid A, Gao YT, Bhakta S, et al. B-catenin mutations in biliary tract cancers: a population-based study in China. Cancer Res. 2001;61:3406-3409.
9. Argani P, Shaukat A, Kaushal M, et al. Differing rates of loss of Dpc4 expression and p53 overexpression among carcinomas of the proximal and distal bile ducts: evidence for a biological distinction. Cancer. 2001;91:1332-1341.
10. Ahrendt SA, Eisenberger CF, Yip L, et al. Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-associated cholangiocarcinoma. J Surg Res. 1999;84:88-93.
11. Ueki T, Hsing AW, Gao YT, et al. Alterations of p16 and prognosis in biliary tact cancers from a population-based study in china. Clin Cancer Res. 2004;10:1717-1725.
12. INK4B/MTS2 genes in biliary tract cancers. Cancer Res. 1995;55:2756-2760.
13. INK4a promoter mutations are frequent in primary sclerosing cholangitis (PSC) and PSC associated cholangiocarcinoma. Gastroenterology. 2002;123:1090-1098.
14. Ito Y, Takeda T, Sakon M, Monden M, Tsujimoto M, Matsuura N. Expression and clinical significance of the G1-S modulators in carcinoma of the extrahepatic bile duct. Anticancer Res. 2000;20:337-344.
15. Ichikawa K, Imura J, Kawamata H, Takeda J, Fujimori T. Down-regulated pi 6 expression predicts poor prognosis in patients with extrahepatic biliary tract carcinomas. Int J Oncol. 2002;20:453-461.
16. Cui X, Hui AM, Li X, et al. Alterations of retinoblastoma protein and p16INK4 protein expression in extrahepatic bile duct carcinomas. Hepatogastroenterology. 2000;47:1216-1220.
17. Klump B, Hsieh CJ, Dette S, Holzmann K, et al. Promoter methylation of INK43/ARF as detected in bile: significance for the differential diagnosis in biliary disease. Clin Cancer Res. 2003;9:1773-1778.
18. Tozawa T, Tamura G, Honda T, et al. Promoter hypermethylation of DAP-kinase is associated with poor survival in primary biliary tract carcinoma patients. Cancer Sci. 2004;95:736-740.
19. Yang B, House MG, Guo M, Herman JG, Clark DP. Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol. 2004;17:1-9.
20. Tannapfel A, Sommerer F, Benicke M, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol. 2002;197:624-631.
21. Lee S, Kim WH, Jung HY, Yang MH, Kang GH. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol. 2002;161:1015-1022.
22. Suto T, Sugai T, Nakamura S, et al. Assessment of expression of p53, MIB-1 (Ki-67 antigen) and argyrophil nucleolar organizer regions in carcinomas of the extrahepatic bile duct. Cancer. 1998;82:86-92.
23. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
24. Koh J, Enders GH, Dynlacht BD, Harlow E. Tumor-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature. 1995;375:506-510.
25. Shim YH, Park HJ, Choi MS, et al. Hypermethylation of the p76 gene and lack of p16 expression in hepatoblastoma. Mod Pathol. 2003;16:430-436.
26. INK4 in human cancer. Proc Natl Acad Sci USA. 1994;91:11045-11049.
27. INK4. Cancer Res. 1994;54:5816-5820.
28. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all human cancers. Cancer Res. 1995;55:4525-4530.
29. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141-196.
30. Seike M, Gemma A, Hosoya Y, et al. Increase in the frequency of gene inactivation by hypermethylation in lung cancer during the process of metastasis and its relation to the status of p53. Clin Cancer Res. 2000;6:4307-4313.
31. Jarrard DF, Modder J, Fadden P, et al. Alterations in the p16/pRb cell cycle checkpoint occur commonly in primary and metastatic human prostatic cancer. Cancer Lett. 2002;185:191-199.
32. Gonzalez-Quevedo R, Garcia-Aranda C, Moran A, et al. Differential impact of p16 inactivation by promoter methylation in non-small cell lung and colorectal cancer: clinical implications. Int J Oncol. 2004;24:349-355.
33. Gessner C, Liebers U, Kuhn H, et al. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer. Eur Respir J. 2002;19:134-140.
34. Schneider-Stock R, Boltze C, Peters B, et al. Differences in loss of p16INK4 protein expression by promoter methylation between left- and right-sided primary colorectal carcinomas. Int J Oncol. 2003;23:1009-1013.
35. Omura-Minamisawa M, Diccianni MB, Chang RC, et al. p16/p14(ARF)cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res. 2001;7:3481-3490.
36. INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol. 2003;129:589-596.
37. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 1996;93:9821-9826.
38. Ouchi K, Matsuno S, Sato T. Long-term survival in carcinoma of the biliary tract: analysis of the prognostic factors in 146 resection. Arch Surg. 1989;124:248-252.
39. Bhuiya MMR, Nimura Y, Kamiya J, Kondo S, Nagino M, Hayakawa N. Clinicopathologic factors influencing survival of patients with bile duct carcinoma: multivariate statistical analysis. World J Surg. 1993;17:653-657.
40. Hui AM, Shi YZ, Li X, Takayama T, Makuuchi M. Loss of p16(INK4) protein, alone and together with loss of retinoblastoma protein, correlate with hepatocellular carcinoma progression. Cancer Lett. 2000;154:93-99.
41. Kang YK, Kim WH, Jang JJ. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma. Hum Pathol. 2002;33:877-883.